Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for ...

If you are wondering whether Biogen's current share price gives you good value for the risk you are taking, you are not alone. Over the last year the stock returned 25.0%. The 3 year and 5 year ...

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous ...

Biogen is diversifying its pipeline to reduce reliance on blockbuster drugs, launching therapies in Alzheimer's, Friedreich Ataxia, postpartum depression, and ALS. The company achieved significant ...

Biogen's Q2 earnings show flat revenue growth but a 31% increase in non-GAAP EPS. The focus is on Alzheimer's drug Leqembi as potential revenue driver, now it has secured full FDA approval and is ...

Biogen has won U.S. Food and Drug Administration breakthrough-therapy designation for its litifilimab drug candidate for the treatment of the chronic autoimmune disease cutaneous lupus erythematosus, ...

Biogen BIIB announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.

Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the company’s ...

Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 11 analysts. The table below summarizes their recent ratings, showcasing the evolving ...

Drug companies Merck and Allergan have expressed interest in taking over biotechnology giant Biogen, The Wall Street Journal reports. People familiar with the matter told the publication that Merck ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are covering the firm, MarketBeat.com reports. Eighteen analysts have rated ...